Diphencyprone and anthralin in alopecia areata

Evaluation of the efficacy and side effects of topical diphencyprone with or without topical anthralin in patients with moderate to severe alopecia areata referring to Razi Hospital Diphencyprone Clinic, 2018- 2019.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020250N4

Enrollment

Registered

2018-06-30

Start date

2018-07-07

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alopecia areata. Alopecia areata

Interventions

Intervention 1: Intervention group 1: 20 patients with moderate to severe alopecia areata who are receiving just topical diphencyprone. Intervention 2: Intervention group 2: 20 patients with moderate

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: moderate to severe alopecia areata

Exclusion criteria

Exclusion criteria: pregnancy or lactation receiving systemic immunosuppressive therapy during recent 3 months severe systemic disease (eg. hepatic or renal failure ) immunosuppression past history of severe reaction or intolerance to diphencyprone or anthralin inability to follow regular visits or cooperation with investigators participation in another clinical trial in recent 4 weeks recent active sever progressive hair loss requiring systemic immunosuppressive therapy

Design outcomes

Primary

Measure	Time frame
Terminal hair regrowth rate with topical diphencyprone in comparison to the combination of topical diphencyprone with topical anthralin in patients with moderate to severe alopecia areata, based of SALT score. Timepoint: before intervention and 3 and 6 months after intervention. Method of measurement: Severity of Alopecia Tool Score.;Rate of change in Severity of Alopecia Tool score than the base value, after intervention and at the end of course of treatment. Timepoint: 3 and 6 months after treatment. Method of measurement: Severity of Alopecia Tool score.;Comparison of response time to treatment with topical diphencyprone exclusively or combination of topical diphencyprone and anthralin. Timepoint: 3 and 6 months after intervention. Method of measurement: time duration (month).	—

Measure

Time frame

Terminal hair regrowth rate with topical diphencyprone in comparison to the combination of topical diphencyprone with topical anthralin in patients with moderate to severe alopecia areata, based of SALT score. Timepoint: before intervention and 3 and 6 months after intervention. Method of measurement: Severity of Alopecia Tool Score.;Rate of change in Severity of Alopecia Tool score than the base value, after intervention and at the end of course of treatment. Timepoint: 3 and 6 months after treatment. Method of measurement: Severity of Alopecia Tool score.;Comparison of response time to treatment with topical diphencyprone exclusively or combination of topical diphencyprone and anthralin. Timepoint: 3 and 6 months after intervention. Method of measurement: time duration (month).

—

Secondary

Measure	Time frame
Evaluation of patients' satisfaction with topical diphencyprone with and without topical anthralin at the end of the survey, using Dermatology Life Quality Index questionnaire. Timepoint: 6 months after treatment. Method of measurement: Dermatology Life Quality Index questionnaire.;Investigating side effects of treatment (eg. dermatitis , lymphadenopathy , folliculitis , urticaria and etc.). Timepoint: 3 and 6 months after treatment. Method of measurement: patient examination and history.	—

Measure

Time frame

Evaluation of patients' satisfaction with topical diphencyprone with and without topical anthralin at the end of the survey, using Dermatology Life Quality Index questionnaire. Timepoint: 6 months after treatment. Method of measurement: Dermatology Life Quality Index questionnaire.;Investigating side effects of treatment (eg. dermatitis , lymphadenopathy , folliculitis , urticaria and etc.). Timepoint: 3 and 6 months after treatment. Method of measurement: patient examination and history.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Romina Daneshmand

Tehran University of Medical Sciences

r-daneshmand@razi.tums.ac.ir+98 21 5560 9951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026